Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
Add more filters










Publication year range
1.
RSC Adv ; 13(35): 24320-24330, 2023 Aug 11.
Article in English | MEDLINE | ID: mdl-37583666

ABSTRACT

The present investigation deals with the evaluation of the wound healing efficacy of sandalwood bark-derived carbon nanospheres loaded with curcumin-embedded polyvinyl alcohol (PVA) nanofiber membranes (NF). Carbon nanospheres (CNS) were prepared by pyrolyzing sandal wood bark powder at 750 °C. The morphology was confirmed by field emission scanning electron micrographs and a rich amount of carbon was confirmed by the energy dispersive X-ray technique. Curcumin, an active wound healing drug was loaded onto synthesized CNS and confirmed by ATR-IR studies. Drug-loaded CNS were anchored in a PVA matrix via electrospun nanofiber fabrication. The fabricated nanofiber membranes were characterized and evaluated for wound healing efficiency. The cytotoxicity assay proved the non-toxic nature of the prepared PVA/CNS-curcumin-loaded NF. Membranes with active CNS/drug showed better antimicrobial activity against S. aureus and E. coli, which was estimated using the zone of inhibition (ZOI) test. The in vitro scratch wound healing assay of prepared PVA/CNS-curcumin nanofibers was efficient enough and showed 92 to 98% wound closure, which was greater than the control (without drug) nanofiber membranes. The PVA nanofiber matrix with interconnected structure and carbon nanostructures together enhanced the wound healing efficacy of the considered wound healing membrane, which is a promising novel approach for future wound healing patches.

2.
RSC Adv ; 13(29): 20373-20406, 2023 Jun 29.
Article in English | MEDLINE | ID: mdl-37425629

ABSTRACT

Heterocyclic compounds are very widely distributed in nature and are essential for life activities. They play a vital role in the metabolism of all living cells, for example, vitamins and co-enzyme precursors thiamine, riboflavin etc. Quinoxalines are a class of N-heterocycles that are present in a variety of natural and synthetic compounds. The distinct pharmacological activities of quinoxalines have attracted medicinal chemists considerably over the past few decades. Quinoxaline-based compounds possess extensive potential applications as medicinal drugs, presently; more than fifteen drugs are available for the treatment of different diseases. Diverse synthetic protocols have been developed via a one-pot approach using efficient catalysts, reagents, and nano-composites/nanocatalysts etc. But the use of homogeneous and transition metal-based catalysts suffers some demerits such as low atom economy, recovery of catalysts, harsh reaction conditions, extended reaction period, expensive catalysts, the formation of by-products, and unsatisfactory yield of products as well as toxic solvents. These drawbacks have shifted the attention of chemists/researchers to develop green and efficient protocols for synthesizing quinoxaline derivatives. In this context, many efficient methods have been developed for the synthesis of quinoxalines using nanocatalysts or nanostructures. In this review, we have summarized the recent progress (till 2023) in the nano-catalyzed synthesis of quinoxalines using condensation of o-phenylenediamine with diketone/other reagents with plausible mechanistic details. With this review, we hope that some more efficient ways of synthesizing quinoxalines can be developed by synthetic chemists.

3.
Int J Biol Macromol ; 246: 125578, 2023 Aug 15.
Article in English | MEDLINE | ID: mdl-37379943

ABSTRACT

Here we present the simple green synthesis of chitosan­silver nanocomposite (CS-Ag NC) by employing kiwi fruit juice as reducing agent. The structure, morphology, and composition of CS-Ag NC were determined using characterization techniques such as XRD, SEM-EDX, UV-visible, FT-IR, particle size, and zeta potential. The prepared CS-Ag nanocomposite was effectively used as catalyst in the reduction of 4-nitrophenol (4-NP) to 4-aminophenol (4-AP) in the presence of NaBH4 as reductant, in aqueous medium at room temperature. The toxicity of CS-Ag NC was assessed on Normal (L929) cell line, Lung cancer (A549) cell line and Oral cancer (KB-3-1) cell line and their respective IC50values observed were 83.52 µg/mL, 66.74 µg/mL and 75.11 µg/mL. The CS-Ag NC displayed significant cytotoxic activity and the cell viability percentage for normal, lung and oral cancer cell lines were found to be 42.87 ± 0.0060, 31.28 ± 0.0045 and 35.90 ± 0.0065 respectively. Stronger cell migration was exemplified by CS-Ag NC and the percentage of wound closure (97.92%) was substantially identical to that of the standard drug ascorbic acid (99.27%). Further CS-Ag nanocomposite was subjected for in vitro antioxidant activity.


Subject(s)
Chitosan , Metal Nanoparticles , Mouth Neoplasms , Nanocomposites , Humans , Antioxidants/pharmacology , Chitosan/chemistry , Silver/chemistry , Spectroscopy, Fourier Transform Infrared , Wound Healing , Nanocomposites/chemistry , Metal Nanoparticles/chemistry , Anti-Bacterial Agents/chemistry
4.
Mol Divers ; 27(1): 517-541, 2023 Feb.
Article in English | MEDLINE | ID: mdl-35301633

ABSTRACT

Throughout the ages the world has witnessed the outbreak of many infectious diseases. Emerging microbial diseases pose a serious threat to public health. Increasing resistance of microorganisms towards the existing drugs makes them ineffective. In fact, anti-microbial resistance is declared as one of the top public health threats by WHO. Hence, there is an urge for the discovery of novel antimicrobial drugs to combat with this challenge. Structural diversity and unique pharmacological effects make natural products a prime source of novel drugs. Staggeringly, in spite of its extensive biodiversity, a prominent portion of microorganism species remains unexplored for the identification of bioactives. Microorganisms are a predominant source of new chemical entities and there are remarkable number of antimicrobial drugs developed from it. In this review, we discuss the contributions of microorganism based natural products as effective antibacterial agents, studied during the period of 2010-2020. The review encompasses over 140 structures which are either natural products or semi-synthetic derivatives of microbial natural products. 65 of them are identified as newly discovered natural products. All the compounds discussed herein, have exhibited promising efficacy against various bacterial strains.


Subject(s)
Anti-Infective Agents , Biological Products , Biological Products/pharmacology , Biological Products/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Infective Agents/pharmacology , Bacteria
5.
RSC Adv ; 12(36): 23661-23674, 2022 Aug 16.
Article in English | MEDLINE | ID: mdl-36090438

ABSTRACT

Quercetin is an abundant plant polyphenol effective against several diseases due to its antioxidant and anti-inflammatory activity. Herein, we report novel polymeric quercetin nanorods and the former decorated with gold nanoparticles for the first time. The prepared conjugates quercetin-polyvinylpyrrolidone (Q-PVP) and quercetin-polyvinylpyrrolidone-gold nanoparticles (Q-PVP-Au) were characterized by UV-visible spectroscopy, Fourier transform infrared, dynamic light scattering, and zeta potential measurements. The surface morphology of conjugates was analyzed by field emission scanning electron microscopy. These conjugates exhibit harmonized rod-like morphology with a narrow size distribution. Furthermore, the quercetin conjugates with nanorod morphology exhibited enhanced and prolonged drug release over a long period. The synthesized conjugates were investigated for lysozyme aggregation kinetics. ThT binding assay, fibril size measurement, and electron microscopy results revealed that conjugates could suppress fibrillogenesis in lysozyme. The highest amyloid aggregation inhibition activity (IC50) was obtained against Q-PVP and Q-PVP-Au at 32 µg mL-1 and 30 µg mL-1 respectively. The amyloid aggregate disintegration activity (DC50) obtained against Q-PVP and Q-PVP-Au was 27 µg mL-1 and 29 µg mL-1 respectively. The present quercetin conjugates exhibit enhanced bioavailability and stability. They were potent inhibitors of lysozyme aggregation that may find applications as a therapeutic agent in neurological diseases like Alzheimer's and Parkinson's.

6.
J Clin Pharm Ther ; 47(7): 915-931, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35288962

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: The main objective of this review is to highlight the most relevant studies since 1990 (to date) in the area of medicinal chemistry aspects to provide a panoramic view to the biologists/medicinal chemists working in this area and would assist them in their efforts to design, synthesize and extract (from natural source) coumarin-based anticonvulsant agents. Also, the structure-activity relationship (SAR) studies are also discussed for further rational design of this kind of derivatives. It is hoped that this review will be helpful for new thoughts in the quest for rational designs of more active and less toxic coumarin-based antiepileptic agents. METHODS: A literature review emphasizing the application of coumarin core as antiepileptic agents identify articles related to the topic; we performed a standardized search from 1990 to November 2021, using search engines like Scifinder, web of Science, Pubmed and Scopus. RESULTS AND DISCUSSION: This review gives an overview of attempts to shed light and compile published reports on coumarin derivatives along with some opinions on different approaches to help the medicinal chemists in designing future generation potent yet safer anticonvulsant agents. The possible structure-activity relationships (SARs) will also be discussed to indicate the direction for the rational design of more effective candidates. WHAT IS NEW AND CONCLUSION: The findings from this review provide new indications or directions for the discovery of new and better drugs from synthetic and naturally occurring coumarins as antiepileptic agents. In our review, we have tried to depict the recent researches which made in the design and development of novel anticonvulsant compounds with coumarin nucleus. Also, SAR of expressed derivatives indicated that the choice of a fitting substitution containing electron-withdrawing/donating groups to coumarin or with some heterocyclic moieties joined to parent coumarin skeleton assumes an essential role in changing the anticonvulsant activity of synthesized derivatives. These findings encourage the scientific community towards the optimization of the pharmacological profile of this structural moiety as an important scaffold for the treatment of epilepsy.


Subject(s)
Antineoplastic Agents , Epilepsy , Anticonvulsants/pharmacology , Anticonvulsants/therapeutic use , Antineoplastic Agents/pharmacology , Chemistry, Pharmaceutical/methods , Coumarins/chemistry , Coumarins/pharmacology , Coumarins/therapeutic use , Epilepsy/drug therapy , Humans , Structure-Activity Relationship
7.
Chem Biodivers ; 18(2): e2000083, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33448662

ABSTRACT

Alzheimer's disease (AD) is a severe age dependent and chronic problem with no cure so far. The available treatments are temporary, acting over short period of time. The main pathological hallmark of the disease includes cholinergic dysfunction, oxidative stress, accumulation of Aß fibrils and tau tangles. In context with the multi-factorial nature of this disease, two different series of molecules were developed to hit the multifactorial disease targets. Mainly, the molecules were designed to inhibit the AChE and aggregation of Aß, and also oxidative damage. Two novel series of TAC-fenbufen/menbutone conjugated molecules were designed, synthesized and bio-assayed. All compounds showed inhibition capacity towards AChE, Aß aggregation and moderate to good radical scavenging capacity. Particularly, five TAC-menbutone molecules showed improved AChE and Aß aggregation inhibition capacity compared to TAC-fenbufen conjugated molecules. Overall, these novel series of molecules may be potential drug lead molecules in the treatment of AD.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/antagonists & inhibitors , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/pharmacology , Tacrine/analogs & derivatives , Tacrine/pharmacology , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Caco-2 Cells , Cholinesterases/metabolism , Drug Discovery , Humans , Molecular Docking Simulation , Protein Aggregates/drug effects , Protein Aggregation, Pathological/drug therapy , Protein Aggregation, Pathological/metabolism , Structure-Activity Relationship
8.
Int J Biol Macromol ; 144: 85-93, 2020 Feb 01.
Article in English | MEDLINE | ID: mdl-31838064

ABSTRACT

Use of biomaterial scaffolds as drug carriers for infected wounds treatment is of wide scope. A series of curcumin/TiO2 complex loaded chitosan scaffolds are fabricated for the same. Synthesized wound dressing material is screened for their morphology, water absorption capacity; in vitro drug release patterns, in vitro antibacterial studies against gram +ve and a gram -ve bacteria, cell viability for 3T3-L1 cell lines as well as in vivo MRSA infected wound healing capability. Formation of curcumin/TiO2 complex was confirmed by X-ray diffraction studies, the anchoring pattern of them on the chitosan scaffold was analyzed by FESEM and EDS mapping. All membranes showed a better performance towards in vitro antibacterial and in vivo wound healing properties than the control ones in 14 days. The bacterial count on wound for a regular time period was measured and the scaffold with higher amount of curcumin in its complex is found to give the better performance, along with skin regeneration due to synergistic effect of curcumin and TiO2.


Subject(s)
Chitosan/chemistry , Curcumin/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Skin/microbiology , Textiles , Tissue Scaffolds/chemistry , Titanium/pharmacology , Wound Healing/drug effects , 3T3-L1 Cells , Animals , Anti-Bacterial Agents/pharmacology , Colony Count, Microbial , Curcumin/chemistry , Drug Liberation , Male , Membranes, Artificial , Methicillin-Resistant Staphylococcus aureus/growth & development , Mice , Microbial Sensitivity Tests , Rats, Sprague-Dawley , Skin/drug effects , Titanium/chemistry , Water , X-Ray Diffraction
9.
Chem Biol Drug Des ; 92(2): 1497-1503, 2018 08.
Article in English | MEDLINE | ID: mdl-29679445

ABSTRACT

Alzheimer's disease (AD), the most common cause of dementia, is a neurodegenerative disorder characterized by progressive deterioration of memory and cognition. The evidenced multifactorial nature of AD has been considered the main reason for the absence of cure so far. Therefore, the development of novel hybrids to treat the disease is very much essential. Focusing on this, a novel series of coumarin-benzofuran hybrids have been designed and screened as anti-Alzheimer's disease agents. The strategy is to obtain an effective mimetic of donepezil, which is acetylcholinesterase inhibitor. Herein, the two main scaffolds namely coumarin and benzofuran are known pharmacophore moieties and we have performed their molecular design, pharmacokinetic descriptor studies for drug-likeliness. Further, in vitro studies such as antioxidant capacity, acetylcholinesterase (AChE) inhibition and amyloid-ß (Aß) self-aggregation inhibition have also been performed. Most importantly, these studies revealed that the newly synthesized hybrids can be versatile and promising drug-like moieties as efficient anti-AD agents.


Subject(s)
Benzofurans/chemistry , Cholinesterase Inhibitors/chemistry , Coumarins/chemistry , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/metabolism , Binding Sites , Cholinesterase Inhibitors/pharmacokinetics , Cholinesterase Inhibitors/therapeutic use , Donepezil/chemistry , Donepezil/metabolism , Drug Design , Humans , Molecular Docking Simulation , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/metabolism , Structure-Activity Relationship
10.
Arch Pharm (Weinheim) ; 351(5): e1700325, 2018 May.
Article in English | MEDLINE | ID: mdl-29611626

ABSTRACT

Tuberculosis (TB) is a highly dreaded, infectious, chronic, airborne disease affecting more than two million people all around the world, with more than eight million cases every calendar year. TB is the second leading infectious cause of death after HIV/AIDS. Over the past few decades, numerous efforts have been undertaken to develop new anti-TB agents. The current frontline therapy for TB consists of administering three or more different drugs (usually isoniazid, rifampin, pyrazinamide, and ethambutol) over an extended period of time. But these drugs will take 6-12 months to cure TB, along with many side effects; hence, there is an urgent need to explore new anti-TB agents. Quinoxaline derivatives are a class of compounds that show a spectrum of biological properties and the interest in these compounds is exponentially growing within the field of medicinal chemistry. Quinoxaline-1,4-di-N-oxide derivatives have shown to improve the biological results and are endowed with anti-viral, anti-cancer, anti-bacterial, and anti-protozoal activities with application in many other therapeutic areas. Since quinoxaline derivatives are regarded as a new class of effective anti-TB candidates, their 1,4-di-N-oxide analogues may show promising in vitro and in vivo anti-TB activities and might be able to prevent the drug resistance to a certain extent. Therefore, the main aim of this review is to focus on important quinoxaline and quinoxaline-1,4-di-N-oxide analogues that have shown anti-TB activities, and their structure-activity relationships for designing anti-TB agents with better efficacies. The present review will be helpful in providing insights for rational designs of more active and less toxic quinoxaline-based anti-TB prodrugs.


Subject(s)
Antitubercular Agents/pharmacology , Oxides/pharmacology , Quinoxalines/pharmacology , Antitubercular Agents/adverse effects , Antitubercular Agents/chemistry , Drug Design , Humans , Oxides/adverse effects , Oxides/chemistry , Quinoxalines/adverse effects , Quinoxalines/chemistry , Structure-Activity Relationship , Tuberculosis/drug therapy , Tuberculosis/microbiology
11.
Eur J Med Chem ; 148: 255-267, 2018 Mar 25.
Article in English | MEDLINE | ID: mdl-29466775

ABSTRACT

Alzheimer's disease (AD) is a severe age-dependent neurodegenerative disorder affecting millions of people, with no cure so far. The current treatments only achieve some temporary amelioration of the cognition symptoms. The main characteristics of the patient brains include the accumulation of amyloid plaques and neurofibrillary tangles (outside and inside the neurons) but also cholinergic deficit, increased oxidative stress and dyshomeostasis of transition metal ions. Considering the multi-factorial nature of AD, we report herein the development of a novel series of potential multi-target directed drugs which, besides the capacity to recover the cholinergic neurons, can also target other AD hallmarks. The novel series of tacrine-hydroxyphenylbenzimidazole (TAC-BIM) hybrid molecules has been designed, synthesized and studied for their multiple biological activities. These agents showed improved AChE inhibitory activity (IC50 in nanomolar range), as compared with the single drug tacrine (TAC), and also a high inhibition of self-induced- and Cu-induced-Aß aggregation (up to 75%). They also present moderate radical scavenging activity and metal chelating ability. In addition, neuroprotective studies revealed that all these tested compounds are able to inhibit the neurotoxicity induced by Aß and Fe/AscH(-) in neuronal cells. Hence, for this set of hybrids, structure-activity relationships are discussed and finally it is highlighted their real promising interest as potential anti-AD drugs.


Subject(s)
Alzheimer Disease/drug therapy , Benzimidazoles/chemistry , Tacrine/chemistry , Amyloid beta-Peptides/antagonists & inhibitors , Benzimidazoles/pharmacology , Cholinesterase Inhibitors/pharmacology , Humans , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/prevention & control , Protein Aggregation, Pathological/prevention & control , Tacrine/pharmacology
12.
J Inorg Biochem ; 179: 82-96, 2018 02.
Article in English | MEDLINE | ID: mdl-29182921

ABSTRACT

A series of (3-hydroxy-4-pyridinone)-benzofuran hybrids have been developed and studied as potential multitargeting drugs for Alzheimer's disease (AD). Their design envisaged mainly to mimic the donepezil drug, a marketed inhibitor of acetylcholinesterase (AChE), and to endow the conjugate molecules with extra-properties such as metal chelation, radical scavenging and inhibition of amyloid peptide (Aß) aggregation. Thus, a set of eleven new hybrid compounds was developed and evaluated for chemical and biological properties, in solution and in neuronal cell environment. The results are discussed in terms of the type of substituents on both main moieties and the linker size. The closest similarity with donepezil, in terms of AChE inhibitory activity, was obtained for the O-benzyl-hydroxypyridinone hybrids containing a 2-methylene linker, although still less active than the drug. However, the free-hydroxypyridinone hybrids present higher activity for the Aß aggregation inhibition, metal chelating capacity and radical scavenging activity. Overall, some compounds demonstrated capacity to exert a multiple action by hitting three- (7d) or four- (8d, 8f) pathophysiological targets of AD. Furthermore, the compounds showed neuroprotective effects in neuronal cells subjected to model stressors of AD, but not significant dependence on the substituent groups. Importantly, the compounds evidenced drug-likeness properties, including good membrane permeability.


Subject(s)
Alzheimer Disease/drug therapy , Benzofurans/pharmacology , Neuroprotective Agents/pharmacology , Pyridones/pharmacology , Amyloid beta-Peptides/chemistry , Benzofurans/chemical synthesis , Benzofurans/chemistry , Biphenyl Compounds/chemistry , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/pharmacology , Copper/chemistry , Free Radical Scavengers/chemical synthesis , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , Iron/chemistry , Iron Chelating Agents/chemical synthesis , Iron Chelating Agents/chemistry , Iron Chelating Agents/pharmacology , Molecular Docking Simulation , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , Peptide Fragments/chemistry , Picrates/chemistry , Protein Multimerization , Pyridones/chemical synthesis , Pyridones/chemistry
13.
Phytomedicine ; 33: 43-52, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-28887919

ABSTRACT

BACKGROUND: Drug discovery from natural products as alternatives for Alzheimer's disease (AD) is a current trend. For which plant is an alternative for searching potential molecule for treating AD. Availability of Cassia tora as weed and abundance in nature makes it as potential source. Many plants group under Leguminosae family has potential medicinal property of which Cassia tora is an appropriate choice, to know potency against AD. Etiology of AD is described by senile plaques and neurofibrillary tangles. The Aß42 has key major role in forming plaques by forming structures like protobirils, oligomers and final fibrilar like structures. Even at in vitro conditions, the peptides have a fibrilar like structure, which was exploited to preliminary screening of natural sources that may be effective in treating AD. HYPOTHESIS/PURPOSE: The design of the study was to unravel the potential medicinal property of Cassia tora for its antioxidant, cholinergic and aggregation inhibition activity. STUDY DESIGN: We evidenced that the methanol (MeOH), n-hexane (n-hex), petroleum ether (PE) and aqueous (aq) extracts from the leaves of Cassia tora (C. tora) were investigated for their inhibitory activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and anti-amyloidogenic assays. The antioxidant effect using 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging, total phenolic and flavonoid contents of the extracts were determined using Folin-Ciocaltaeu's and aluminum chloride (AlCl3) reagents, respectively. RESULTS: The methanol extract of C. tora exerted the highest inhibition against AChE (55.38 ± 2.28%) and BChE inhibition (50.02 ± 0.79%) at 100µg/ml concentration. The methanol extract was also found more active in the antioxidant test. The aggregation kinetics was monitored using thioflavin-T (ThT) assay and transmission electron microscopy (TEM) technique. CONCLUSION: The results showed that C. tora methanol extract is able to inhibit the Aß42 aggregation from monomers and oligomers and also able to dis-aggregate the pre-formed fibrils. The study provides an insight on finding new natural products for AD therapeutics.


Subject(s)
Antioxidants/pharmacology , Cassia/chemistry , Cholinergic Agents/pharmacology , Plant Extracts/pharmacokinetics , Acetylcholinesterase , Alzheimer Disease/drug therapy , Antioxidants/isolation & purification , Butyrylcholinesterase , Cholinergic Agents/isolation & purification , Cholinesterase Inhibitors/isolation & purification , Cholinesterase Inhibitors/pharmacology , Flavonoids/pharmacology , Humans , Phenols/pharmacology , Plant Leaves/chemistry
14.
Eur J Med Chem ; 138: 1002-1033, 2017 Sep 29.
Article in English | MEDLINE | ID: mdl-28759875

ABSTRACT

Among sulfur containing heterocycles, benzothiophene and its derivatives are at the focus as these candidates have structural similarities with active compounds to develop new potent lead molecules in drug design. Benzo[b]thiophene scaffold is one of the privileged structures in drug discovery as this core exhibits various biological activities allowing them to act as anti-microbial, anti-cancer, anti-inflammatory, anti-oxidant, anti-tubercular, anti-diabetic, anti-convulsant agents and many more. Further, numerous benzothiophene-based compounds as clinical drugs have been extensively used to treat various types of diseases with high therapeutic potency, which has led to their extensive developments. Due to the wide range of biological activities of benzothiophene, their structure activity relationships (SAR) have generated interest among medicinal chemists, and this has culminated in the discovery of several lead molecules against numerous diseases. The present review is endeavoring to highlight the progress in the various pharmacological activities of benzo[b]thiophene derivatives. It is hoped that this review will be helpful for new thoughts in the quest for rational designs of more active and less toxic benzothiophene-based medicinal drugs, as well as more effective diagnostic agents and pathologic probes. Also, SAR studies that highlight the chemical groups responsible for evoking the potential activities of benzothiophene derivatives are studied and compared.


Subject(s)
Thiophenes/pharmacology , Animals , Chemistry, Pharmaceutical , Disease , Humans , Molecular Structure , Structure-Activity Relationship , Thiophenes/chemical synthesis , Thiophenes/chemistry
15.
Pharmacol Rep ; 69(2): 281-295, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28171830

ABSTRACT

The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. In this context, oxygen heterocycles exhibit diverse biological and pharmacological activities due in part to the similarities with many natural and synthetic molecules with known biological activity. Among oxygen containing heterocycles, benzofuran (synthetic and natural isolated) and its derivatives have attracted medicinal chemists and pharmacologists due to their pronounced biological activities and their potential applications as pharmacological agents such as antioxidant, antitumor, antiplatelet, antimalarial, antiinflammatory, antidepressant and anticonvulsant properties. There are also an amazing number of approved benzofuran-containing drugs in the market as well as compounds currently going through different clinical phases or registration statuses. Due to the wide range of biological activities of benzofurans, their structure activity relationships have generated interest among medicinal chemists, and this has culminated in the discovery of several lead molecules in numerous disease conditions. Recently, this scaffold has emerged as a pharmacophore of choice for designing antioxidant drug development as their derivatives have shown excellent results through different mechanism of action. This review focused on the recent development of benzofuran derivatives as antioxidant agents (including natural products) and their antioxidant activities; summarize the structure property, hoping to inspire new and even more creative approaches. Also, this study systematically provides a comprehensive report on current developments in benzofuran-based compounds as antioxidant agents and is also helpful for the researchers working on a substitution pattern around the nucleus, with an aim to help medicinal chemists to develop structure activity relationships (SAR) on these derivatives as antioxidant drugs.


Subject(s)
Antioxidants/therapeutic use , Benzofurans/therapeutic use , Heterocyclic Compounds/therapeutic use , Drug Design , Drug Discovery/methods , Humans , Structure-Activity Relationship
16.
Pharmacol Rep ; 68(6): 1254-1265, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27686965

ABSTRACT

Mycobacterium tuberculosis (Mtb) is considered as one of the precarious bacterial infections around the world. Through a projected 8.7 million new tuberculosis (TB) cases and 1.4 million mortalities per annum, this deadly infection resulted insubstantial amount of human deaths than any other single organism bacterial infections. TB is one of India's most threatening human health problems and it accounts for approximately 33% of the global health issues. Subsequently, for TB there is an imperative need for the improvement of existing drug candidates with newer targets and specified mechanism of action. Within the wide spectra of heterocycles, benzimidazole and its substituted analogues were evidenced promising biological efficacies enabling them to perform as new drug or prodrug candidates. Exceptional structural features of this class of heterocycle and versatile biological applications made it a privileged structural backbone in new drug design and discovery. Majorly, 2,5- and 2,6-disubstituted benzimidazole derivatives shown to induce significant antiTB potential. To seek more insights on this unique feature of benzimidazole candidates, there is an urgency to assemble the recent advances in this promising area. This review presents an overview of the recent advancements and focuses on the structural features responsible for unique antiTB applications and compiled published reports on benzimidazole derivatives emphasizing on different approaches employed for their syntheses in order to help medicinal and clinical chemists in designing next generation, yet effective and safer antiTB candidates.


Subject(s)
Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Drug Design , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Antitubercular Agents/therapeutic use , Benzimidazoles/therapeutic use , Humans , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/physiology , Tuberculosis/drug therapy
17.
Chem Biol Drug Des ; 87(1): 101-11, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26256122

ABSTRACT

Alzheimer's disease (AD) is a devastating age-dependent neurodegenerative disorder. The main hallmarks are impairment of cholinergic system and accumulation in brain of beta-amyloid (Aß) aggregates, which have been associated with oxidative damage and dyshomeostasis of redox-active biometals. The absence of an efficient treatment that could delay or cure AD has been attributed to the complexity and multifactorial nature of this disease. With this in mind and the recent interest on natural-based drugs, we have explored a set of natural-based hybrid compounds by conjugation of a tacrine moiety with an S-allylcysteine (garlic constituent) or S-propargylcysteine moiety aimed at improving the cholinergic system and neuroprotective capacity. The docking modeling studies allowed the selection of linkers to optimize the bimodal drug interaction with acetylcholinesterase enzyme (AChE) active site. The compounds were evaluated for some representative biological properties, including AChE activity and Aß aggregation inhibition, as well as for their neuroprotective activity to Aß- and ROS-induced cellular toxicity. The most promising results were achieved by compounds 9d for the AChE inhibition and 9l for the remarkable prevention of superoxide production and Aß-induced cellular toxicity.


Subject(s)
Alzheimer Disease/drug therapy , Cysteine/chemistry , Tacrine/therapeutic use , Acetylcholinesterase/drug effects , Blood-Brain Barrier , Cell Line, Tumor , Cholinesterase Inhibitors/pharmacology , Humans , Tacrine/chemistry , Tacrine/pharmacology
18.
Future Med Chem ; 7(10): 1305-33, 2015.
Article in English | MEDLINE | ID: mdl-26144266

ABSTRACT

Late transition metal complexes that bear N-heterocyclic carbene (NHC) ligands have seen a speedy growth in their use as both, metal-based drug candidates and potentially active homogeneous catalysts in a plethora of C-C and C-N bond forming reactions. This review article focuses on the recent developments and advances in preparation and characterization of NHC-metal complexes (metal: silver, gold, copper, palladium, nickel and ruthenium) and their biomedical applications. Their design, syntheses and characterization have been reviewed and correlated to their antimicrobial and anticancer efficacies. All these initial discoveries help validate the great potential of NHC-metal derivatives as a class of effective antimicrobial and anticancer agents.


Subject(s)
Anti-Infective Agents/chemistry , Antineoplastic Agents/chemistry , Coordination Complexes/chemistry , Heterocyclic Compounds/chemistry , Metals/chemistry , Methane/analogs & derivatives , Animals , Anti-Infective Agents/pharmacology , Anti-Infective Agents/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Bacteria/drug effects , Bacterial Infections/drug therapy , Coordination Complexes/pharmacology , Coordination Complexes/therapeutic use , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Humans , Metals/pharmacology , Metals/therapeutic use , Methane/chemistry , Methane/pharmacology , Methane/therapeutic use , Neoplasms/drug therapy
19.
J Inorg Biochem ; 151: 58-66, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26119099

ABSTRACT

The complexity and multifactorial nature of neurodegenerative diseases turn quite difficult the development of adequate drugs for their treatment. Multi-target analogues, in conjugation with natural moieties, have been developed in order to combine acetylcholinesterase (AChE) inhibition with antioxidant properties, metal-binding capacity and inhibition of amyloid-ß (Aß) aggregation. Due to the recent interest on natural-based drugs and also the importance of studying the role of transition metal ions in the disease process, we herein evaluate the copper chelating capacity and inhibitory ability for self- and Cu-induced Aß1-42 aggregation of two nature-base hybrid model compounds obtained from conjugation of a tacrine moiety with a S-allylcystein (1) or S-propargylcystein (2) moiety. Both compounds show a moderate chelating power towards Cu(II) (pCu 7.13-7.51, CL/CCu=10, CCu=10(-6)M, pH7.4), with predominant formation of 1:1 complex species (CuL, CuH-1L) for which the coordination sphere involves the N-amide and the NH2 amine of the cysteine derivative as well as the NH of tacrine. The compounds are able to improve the inhibition of Aß aggregation in the presence of Cu(II) and this is slightly more relevant for the allyl derivative (1), a stronger copper chelator, than for the propargyl (2). Moreover, the presence of a chloro atom in the tacrine moiety and the size of the chain length between the two NH groups appeared also to improve the inhibition capacity for Aß aggregation.


Subject(s)
Coordination Complexes/chemistry , Copper/chemistry , Tacrine/chemistry , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/chemistry , Chelating Agents/chemistry , Cholinesterase Inhibitors/chemistry , Cysteine/chemistry , Humans , Hydrogen-Ion Concentration , Models, Molecular , Molecular Structure , Spectrometry, Mass, Electrospray Ionization
20.
Eur J Med Chem ; 100: 257-69, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-26112067

ABSTRACT

Tuberculosis (TB) is still a challenging worldwide health problem and mycobacterium tuberculosis (MTB) remains one of the most deadly human pathogens. TB is the second leading infectious cause of mortality today behind only HIV/AIDS. The impetus for developing new structural classes of antituberculosis drugs comes from the emergence of multi-drug resistant (MDR) strains. The development of MDR strains to commonly used drugs is due to, longer durations of therapy as results of resistance, and the resurgence of the disease in immune compromised patients. Therefore, there is an urgent need to explore new antitubercular (anti-TB) agents. Ironically, the low number of potentially new chemical entities which can act as anti-TB candidates is of great importance at present situation. Considering the severity of the problem, WHO has prepared a strategic plan in Berlin declaration 2007 to stop TB, globally. Among the oxygen heterocycles, coumarin derivatives are important motifs, which can be widely found in many natural products, and many of them displaying diverse biological activities. This spectacular spectrum of applications has intrigued organic and medicinal chemists for decades to explore the natural coumarins or their synthetic analogs for their applicability as anti-TB drugs. To pave the way for the future research, there is a need to collect the latest information in this promising area. In the present review, we collated published reports on coumarin derivatives to shed light on the insights on different types of methods reported for their preparations, characterizations and anti-TB applications, so that its full therapeutic potential class of compounds can be utilized for the treatment of tuberculosis. Therefore, the objective of this review is to focus on important coumarin analogs with anti-TB activities, and structure-activity relationships (SAR) for designing the better anti-TB agents. It is hoped that, this review will be helpful for new thoughts in the quest for rational designs of more active and less toxic coumarin-based anti-TB drugs.


Subject(s)
Antitubercular Agents/pharmacology , Coumarins/pharmacology , Drug Design , Tuberculosis/drug therapy , Antitubercular Agents/chemical synthesis , Antitubercular Agents/chemistry , Coumarins/chemical synthesis , Coumarins/chemistry , Humans , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Tuberculosis/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...